Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn about recent paper by J. Rodon et al., titled “First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration” published on ESMO Annals of Oncology.
Authors: J. Rodon, H. Prenen, A. Sacher, M. Villalona-Calero, N. Penel, A. El Helali, S. Rottey, N. Yamamoto, F. Ghiringhelli, M.E. Goebeler, T. Doi, S. Postel-Vinay, C.-C. Lin, C. Liu, C.-H. Chuang, K. Keyvanjah, T. Eggert, B.H. O’Neil
“Phase I Results for AMG 193
Exciting developments in oncology! A recent phase I study has shown that AMG 193, a novel PRMT5 inhibitor, exhibits significant antitumor activity in patients with MTAP-deleted solid tumors.
Key Highlights:
- Objective Response Rate: 21.4% across eight tumor types, including non-small cell lung cancer, pancreatic adenocarcinoma, and biliary tract cancer.
- Safety Profile: Favorable, with no significant myelosuppression observed. Mainly nausea, fatigue and vomiting observed with 2 cases needing to discontinue therapy.
- Mechanism of Action: Selectively induces synthetic lethality in MTAP-deleted tumor cells.
These findings suggest that AMG 193 could become a valuable targeted therapy for various MTAP-deleted cancers.”